WideCells Group Plc (LON:WDC) CEO João Andrade talks to DirectorsTalk about UK’s first insurance product for stem cell treatment, CellPlan now being available for purchase. João provides more information on what CellPlan is and why someone would want to purchase it, explains how Biovault and the e-commerce platform will work, what kind of revenues WideCells Group look to generate and other agreements in the pipeline.
WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments accessible and affordable. In June 2017, the Group was ranked as the 21st most disruptive company globally by DISRUPT 100, an annual index celebrating the businesses with the most potential to influence, change or create new global markets.
With this in mind, it has created three divisions:
· CellPlan: the world’s first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process
· WideCells: the Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Centre to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising in stem cell storage.
· WideAcademy: developing an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.
The Group has built an experienced senior management team that has been integral to the development of its growth and business to date.